Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
<p>Abstract</p> <p>Background</p> <p>Fabry disease is a lysosomal X-linked enzyme deficiency of α-galactosidase A associated with an increased mortality and morbidity due to renal failure, cardiac disease and early onset stroke.</p> <p>Methods</p> <...
Main Authors: | Herscovitch Peter, Schiffmann Raphael, Altarescu Gheona, Moore David F |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2002-06-01
|
Series: | BMC Neurology |
Online Access: | http://www.biomedcentral.com/1471-2377/2/4 |
Similar Items
-
Arterial Wall Properties and Womersley Flow in Fabry Disease
by: Dimitriadis Emilios, et al.
Published: (2002-01-01) -
Enzyme Replacement Therapy for Fabry Disease
by: Maria Dolores Sanchez-Niño PhD, et al.
Published: (2016-11-01) -
Enzyme replacement therapy in Fabry Disease: the importance of dose
by: Juan Manuel Politei, et al.
Published: (2017-04-01) -
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
by: Fernando C Fervenza, et al.
Published: (2008-11-01) -
An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
by: Goker-Alpan O, et al.
Published: (2016-05-01)